Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of$0.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of$0.06, delivering a surprise of 40%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Theravance Bio, wh ...